Somewhat related, bryostatin 1 entered phase II clinical trials for testing in the treatment of Alzheimer’s Disease as a PKC activator, after it was also experimentally used in phase I trials for various forms of cancer [137,138,139]. The gene discussed is PRRT2; the disease is early-onset autosomal dominant Alzheimer disease.